Nanosonics Director Adjusts Equity Holdings
Nanosonics Limited (AU:NAN) announced a change in director Michael Kavanagh's equity holdings, acquiring 109,685 ordinary shares through the Omnibus Equity Plan. This adjustment aims to align management interests with shareholder value, potentially influencing investor confidence. The latest analyst rating for AU:NAN is a Buy with a price target of A$4.50. Nanosonics specializes in medical technology, particularly infection prevention solutions, and has a current market cap of A$1.25B.
Nanosonics Limited ( (AU:NAN) ) has shared an update.
Nanosonics Limited announced a change in the director’s interest, specifically regarding Mr. Michael Kavanagh’s holdings. The change involved the exercise of performance and service rights under the Nanosonics Omnibus Equity Plan, resulting in the acquisition of 109,685 ordinary shares. This adjustment in the director’s holdings reflects the company’s ongoing commitment to aligning management interests with shareholder value, potentially impacting investor confidence and market perception.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$4.50 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
More about Nanosonics Limited
Nanosonics Limited operates in the medical technology industry, specializing in infection prevention solutions. The company is known for its innovative products, including the trophon® EPR, which is a market-leading device for high-level disinfection of ultrasound probes.
Average Trading Volume: 776,916
Technical Sentiment Signal: Buy
Current Market Cap: A$1.25B
Learn more about NAN stock on TipRanks’ Stock Analysis page.
